Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q6UX46

UPID:
ALKL2_HUMAN

ALTERNATIVE NAMES:
Augmentor alpha

ALTERNATIVE UPACC:
Q6UX46; B5MC76

BACKGROUND:
The protein ALK and LTK ligand 2, known alternatively as Augmentor alpha, serves as a physiological ligand for the receptor tyrosine kinases LTK and ALK. Its binding leads to the activation of these receptors, a critical step in neural development and the regulation of energy expenditure. The activation mechanisms differ, with LTK activation being direct and ALK requiring additional heparin-binding.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of ALK and LTK ligand 2 offers a promising pathway to novel therapeutic approaches. Given its significant role in neural development and energy balance, targeting this protein could yield breakthroughs in treating related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.